MRI Reveals Altered Brain Structure in Fetuses Exposed to Alcohol

In the first MRI-based study to investigate pre-natal alcohol exposure, researchers found significant changes in the brain structure of fetuses exposed to alcohol compared to healthy controls. Results of the study are being presented today at the annual meeting of the Radiological Society of North America (RSNA).

“Fetal alcohol syndrome is a worldwide problem in countries where alcohol is freely available,” said Gregor Kasprian, M.D., associate professor of radiology at the Medical University of Vienna in Austria. “It’s estimated that 9.8% of all pregnant women are consuming alcohol during pregnancy, and that number is likely underestimated.”

Fetal alcohol syndrome is the most severe form of a group of conditions called fetal alcohol spectrum disorders that result from alcohol exposure during pregnancy. Babies born with fetal alcohol spectrum disorders may have specific physical features, learning disabilities, behavioral problems or speech and language delays. According to Dr. Kasprian, one in 70 pregnancies with alcohol exposure results in fetal alcohol syndrome.

“There are many postnatal studies on infants exposed to alcohol,” Dr. Kasprian said. “We wanted to see how early it’s possible to find changes in the fetal brain as a result of alcohol exposure.”

For the study, researchers recruited 500 pregnant women who were referred for a fetal MRI for clinical reasons. On an anonymous questionnaire, 51of the women admitted to consuming alcohol during their pregnancy. The questionnaires used were the Pregnancy Risk Assessment Monitoring System (PRAMS), a surveillance project of the Centers for Disease Control and Prevention and health departments, and the T-ACE Screening Tool, a measurement tool of four questions that identify risk drinking.

“We provided a safe environment where women could feel comfortable honestly answering the questions,” Dr. Kasprian said.

After eliminating some of the fetal MRIs for reasons such as structural brain anomalies and/or poor image quality, the final study group consisted of 26 fetal MRI exams from 24 alcohol-positive fetuses and a control group of 52 gender- and age-matched healthy fetuses. At the time of imaging, fetuses ranged in age between 20 and 37 weeks.

The researchers used super-resolution imaging, which allowed them to create one dataset to re-construct each fetal brain. Next, they completed an analysis of 12 different brain structures, computing total brain volume and segment volumes of specific brain compartments.

“One of the main hallmarks of our study is that we investigated so many smaller sub-compartments of the brain,” said co-author Marlene Stuempflen, M.D., scientific researcher at the Medical University of Vienna.

The statistical analysis revealed two major differences in the alcohol-exposed fetuses compared to healthy controls: an increased volume in the corpus collosum and a decreased volume in the periventricular zone.

“This is the first time that a prenatal imaging study has been able to quantify these early alcohol-associated changes,” Dr. Stuempflen said.

The corpus collosum is the main connection between the brain’s two hemispheres. Dr. Stuempflen noted that it is fitting that this very central structure is affected, because the clinical symptoms of fetal alcohol spectrum disorders are highly heterogenous, or diverse, and cannot be pinpointed to one specific substructure of the brain.

“The changes found in the periventricular zone, where all neurons are born, also reflect a global effect on brain development and function,” she said.

The researchers said finding a thicker corpus collosum in the alcohol-positive fetuses was surprising because the corpus collosum is thinner in infants with fetal alcohol spectrum disorders.

“It appears that alcohol exposure during pregnancy puts the brain on a path of development that diverges from a normal trajectory,” Dr. Kasprian said. “Fetal MRI is a very powerful tool to characterize brain development not only in genetic conditions, but also acquired conditions that result from exposure to toxic agents.”

Additional co-authors are Ernst Schwartz, M.Sc., Mariana Diogo, M.D., Ph.D., Sarah Glatter, M.D., M.M.Sc., Birgit Pfeiler, Victor Schmidbauer, M.D., Lisa Bartha-Doering, Ph.D., Rainer Seidl, M.D., Elisabeth Krampl-Bettelheim, M.D., and Daniela Prayer, M.D.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version